Background Prior studies have suggested that percutaneous transmyocardial laser revascularization (PTMR) may be effective as a sole treatment modality in reducing angina in patients with severe coronary artery disease and no revascularization alternatives. The safety and efficacy of the hybrid or adjunctive use of PTMR during the same procedure as percutaneous intervention (PCI) has not previously been reported.
Methods
A US phase I feasibility study was therefore performed to determine whether PTMR performed in the same myocardial territory as PCI is able to ameliorate symptomatic recurrence from restenosis.
Results After successful and uncomplicated PCI in 26 patients with class III-IV angina and lesion(s) at high risk for restenosis, PTMR was performed in the same myocardial territories subtended by the treated vessel(s). Major periprocedural adverse events (death, Q-wave myocardial infarction, and bypass surgery) occurred in 3 (11.5%) patients, as the result of subacute vessel closure in 2 patients, and tamponade in the third. Cumulative 6-month mortality rate was 19.2%, including 2 late deaths between 3 and 4 months after discharge (1 death caused by late stent closure and 1 unexplained death during sleep.) Late repeat revascularization for restenosis in the PCI plus PTMR treated target vessel was required in 19.2% of patients, and an additional 11.5% of patients had class III-IV angina at 6-month follow-up.
Conclusions
These data demonstrate that in a patient population at high risk for restenosis, recently created PTMR channels are not protective against severe ischemia caused by acute vessel closure and that late symptomatic restenosis after PCI may still frequently occur despite PTMR in the same region. (Am Heart J 2001;142:679-83.)
of ≥1 lesion at high risk for restenosis was planned were eligible for enrollment into this US phase I study, which was performed under an FDA-approved Investigational Device Exemption. Lesion entry criteria required 1 or more of the following conditions to be present: lesion length >15 mm or reference vessel diameter <3.0 mm; ostial location; bifurcation lesion (both limbs requiring intervention); saphenous vein graft stenosis; and chronic total occlusion (successfully treated). Patients undergoing PCI and not meeting these anatomic criteria were also eligible for enrollment if diabetes mellitus was present (insulin or oral drug treated) or if angioplasty was required of ≥2 stenoses. Patients were excluded if any of the following were present: left ventricular ejection fraction <30%; myocardial infarction within 3 months or prior percutaneous transluminal coronary angioplasty within 6 months; the presence of aortic stenosis, aortic valve replacement, left ventricular aneurysm, or suspected mural thrombus; inability to perform a baseline exercise stress test for any reason other than unstable angina (or electrocardiographic conditions precluding the accurate diagnosis of ischemia such as left bundle branch block, left ventricular hypertrophy, or Wolf-Parkinson-White syndrome); echocardiographic wall thickness of <9 mm in the laser target myocardial territory (or echocardiography not performed or inadequate); severe ventricular arrhythmias within the preceding week; noncardiac conditions with anticipated life expectancy <1 year; participation in another investigational drug or device study; or inability or unwillingness to provide informed consent.
The study protocol was approved by the investigational review boards of each of the participating hospitals. All patients signed written informed consent.
Study protocol and laser PTMR procedure
Baseline transthoracic echocardiography was required before catheterization in all study patients. PCI of the target lesions(s) was performed with the use of standard FDAapproved devices and techniques. If PCI was successful in all attempted lesions (diameter stenosis <50% with Thrombolysis In Myocardial Infarction [TIMI] 3 flow, with no angiographic complications such as transient or sustained acute closure, slow or no reflow, distal thromboemboli, and so forth, noted), PTMR was then performed in the same myocardial territories subtended by the treated vessel(s). PTMR was performed with the Eclipse Holmium-YAG laser with fluoroscopic guidance with the use of a previously described technique. 2, 5 By protocol, creatine phosphokinase-MB determinations were to be drawn every 8 hours 3 times after the procedure. Patients were discharged when clinically stable. Clinical follow-up was performed by office visit, interview, or telephone call at 1, 3, and 6 months after discharge.
Statistical analysis
Categoric variables are presented as n (%). Continuous variables are presented as mean ± SD. By intention-to-treat analysis, outcomes are reported for the entire population (n = 27), whether or not PTMR was performed. Treatment-delivered analysis is reported when appropriate in all patients in whom PTMR was attempted (n = 26).
Results

Baseline features
Between October 1997 and April 1998, 27 patients were enrolled into the study at 5 US sites. The baseline demographic and angiographic characteristics appear in Table I . The population was elderly, with a high proportion of patients with diabetes, prior myocardial infarction and heart failure, prior revascularization, and triple-vessel disease. Intravenous nitroglycerin was required for severe unstable angina in more than one third of patients.
Procedural, in-hospital, and 30-day results
PCI was performed in all 27 patients, including balloon angioplasty in 96%, atheroablation in 19%, and stenting in 42%. PCI was successful in 26 (96%) patients, in whom PTMR was then performed in the same myocardial territory (Table II) .
Procedural complications and 30-day safety data appear in Table III . Two patients died before discharge, and a third patient died several days after discharge. In the first patient, stenting was performed of the proximal left anterior descending (LAD) artery, followed by successful, uncomplicated PTMR of the anterior wall. Subacute vessel closure of the mid-distal LAD caused by distal wire trauma occurred 1 day later. This complication was not believed to be related to PTMR. The second death occurred in a patient with in-stent restenosis from a previous procedure, wherein the LAD stent was found to be "bent" and could not be expanded. During this attempt, the patient had procedural chest pain and hypotension, and salvage PTMR was attempted. The PTMR guide, however, could not be positioned in stable fashion, and the laser was never fired. The patient became progressively hypotensive and died. This complication was believed to be unrelated to the PTMR procedure.
In the third patient, PTMR of the lateral wall was performed after triple-vessel stenting. Chest pain with pericardial effusion developed acutely but initially stabilized, and the patient was discharged, only to be readmitted 2 days later with pericardial tamponade. Emergency bypass surgery was performed, which was complicated by massive acute anterior myocardial infarction, electromechanical dissociation, and death. Postmortem pathologic examination demonstrated a healed 2-mm diameter lateral wall perforation (the PTMR site), with extensive anterior myocardial rupture caused by acute LAD transmural infarction. This complication was attributed to the PTMR procedure.
Echocardiographically documented pericardial effusion consistent with left ventricular perforation occurred in 3 (11.5%) patients, including the one case of tamponade described above. The other minor perforations resulted in no adverse sequelae, and the patient was discharged the following day. Other events directly related to the PTMR procedure were infrequent and relatively minor (Table III) . The mean length of hospital stay after the procedure was 1.8 ± 1.5 days.
Late outcomes
Whereas class III-IV angina was present in 100% of patients before the procedure, 19.2% and 11.5% of patients had class III-IV angina at 3 and 6 months, respectively (Figure 1) . Two additional deaths occurred between 1 and 6 months after the procedure; 1 patient died of stent occlusion at 90 days, and 1 patient unexpectedly died during sleep 124 days after discharge. Five (19.2%) of 26 patients in whom PTMR was performed required late repeat revascularization within 6 months for restenosis in the target vessel supplying the myocardial territory treated by the laser; all were class I-II at 6 months (Table IV) .
Discussion
The current phase I experience demonstrates that recently created PTMR channels are not protective against severe ischemia caused by acute vessel closure within days of angioplasty and that late symptomatic restenosis after PCI may still frequently occur despite PTMR in the same myocardial region.
Early recurrent ischemia after hybrid PCI plus PTMR
After initial reports that newly formed PTMR channels may remain patent and supply significant perfusion to ischemic myocardium, 6,7 attempts were made to prevent or treat acute myocardial infarction with laser myocardial revascularization, with variable success. 8, 9 In contrast, the observation from this study that severe ischemia with acute myocardial infarction may still occur after PCI despite successful PTMR in the same myocardial territory supports alternative experimental evidence that acutely created PTMR channels do not carry sufficient blood flow to salvage acutely ischemic myocardium. 10, 11 The high early event rate in this study is also of note. Given the limited sample size, it is possible that chance played a role in the observed frequency of adverse events. However, at least one complication was directly attributable to the simultaneous performance of PCI and PTMR (tamponade from PTMR requiring surgery, ultimately resulting in acute epicardial vessel closure). An expanded experience would be required to determine whether staging the PCI and PTMR procedures would be prudent in patients with high-risk features.
Late recurrent ischemia after hybrid PCI plus PTMR
Prior nonblinded studies have found that stand-alone PTMR is associated with reduced angina in chronically ischemic patients with end-stage coronary artery disease and no revascularization alternatives. [1] [2] [3] The time course of this effect is usually within the first several months and is sustained in most patients for at least 1 Table III . In-hospital complications and 30-day adverse events after PCI plus PTMR in 26 patients year. [1] [2] [3] 5 It was thus hypothesized that the creation of PTMR channels in the same myocardial territory subtended by the epicardial vessel undergoing PCI might ameliorate symptomatic restenosis, which usually occurs during the same time frame. Although the mechanism of benefit from PTMR is not well understood (reduced ischemia from angiogenesis 12-14 versus denervation 15, 16 versus placebo effect 17 ), the fact that in the current series symptomatic restenosis requiring repeat target vessel revascularization within the first 6 months occurred in 19% of patients and that an additional 12% of patients still had class III-IV angina at 6 months suggests that the "PTMR effect" is inadequate to improve the symptomatic state of many patients who have severe epicardial restenosis. Although the absence of a control group and routine angiographic follow-up precludes knowing whether any patients did in fact benefit from hybrid PTMR plus PCI, the relatively high recurrence rate, in concert with the risk and cost of the additional procedure, make it highly unlikely that "prophylactic PTMR" in the same myocardial territory as PCI and during the same procedure should be pursued as a viable strategy for patients at high risk for restenosis, at least with the current technology. Furthermore, of concern is the fact that 2 (7.7%) patients died 3 to 4 months after the procedure (one from acute target vessel closure and one from sudden death). Given the fact that restenosis within the first 6 months typically occurs as recurrent and progressive angina and rarely as acute myocardial infarction or sudden death, 18, 19 this observation raises the worrisome possibility that in some patients, PTMR may indeed mask symptomatic restenosis until acute vessel closure occurs, which then overwhelms any beneficial PTMR effect on symptoms, resulting in severe ischemia or acute myocardial infarction. Because medically treated restenosis often stabilizes and even regresses, [18] [19] [20] this study suggests that PTMR does not provide sufficient relief of ischemia in severe cases of restenosis.
Several reasons may be hypothesized for the apparent ineffectiveness of hybrid PTMR plus PCI in the same territory. First, because PTMR was performed with fluoroscopic guidance only, it is possible that channels were not created in the proper myocardial regions. Against this possibility is the observation that stand-alone PTMR performed with the same system and myocardial guidance technique has been shown to be effective in the majority of patients with end-stage ischemic heart disease. 2, 5 Second, because ischemic myocardium is a potent stimulus for growth factor release and angiogenesis, 21, 22 it is possible that alleviating the epicardial stenosis before PTMR actually blunts the beneficial effect of the procedure. Third, PTMR may provide a modest but acceptable degree of analgesia or relief of ischemia sufficient for most patients with chronic ischemia and advanced coronary artery disease (in whom functioning 
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collaterals already exist) but that this moderate level of protection is inadequate for patients without chronic ischemia or an extensive collateral network in whom a severe epicardial stenosis develops.
Implications for future investigation
Although it must be acknowledged that the number of patients studied was small and the inclusion criteria broad, the symptomatic and angiographic recurrence rates were sufficiently high to justify concluding that based on the current investigation, PTMR should not be performed in the same myocardial territory during the same procedure as PCI. However, hybrid PTMR plus PCI may still potentially play an important role in 2 common patient subsets: (1) the patient with multivessel disease, successfully revascularized in one myocardial territory with an untreatable chronic total occlusion or diffuse disease in an anatomically distinct area, in which PTMR can be performed, and (2) the stable patient with single-vessel disease and a chronically occluded coronary artery, in whom PTMR in the same territory after unsuccessful but uncomplicated PCI may offer superior symptomatic relief compared with otherwise intended chronic medical therapy. Both these scenarios offer the theoretically advantageous substrate of PTMR in chronically ischemic myocardium supplied by a permanently closed or insufficient epicardial coronary system. Any realized benefits will have to be weighed against potential additive risks of PTMR, particularly in light of the high occurrence rate of early and late major adverse cardiac events in the present series. Randomized trials are presently underway to examine the utility of hybrid PTMR in both these settings.
